Changsha, October 18, 2025 – VJTBio made its debut at the 14th Leman China Swine Conference & World Pork Expo. Focusing on the core demand for improved reproductive efficiency, the company showcased its National Class I New Veterinary Drug VJT101 (Recombinant Porcine Follitropin Fc Fusion Protein for Injection) alongside multiple other products, comprehensively demonstrating the company's achievements in drug efficacy, R&D capabilities, and technical services.
The grand opening of the conference took place at the Changsha International Conference and Exhibition Center, featuring an exhibition area of 100,000 square meters. It brought together over 800 globally renowned companies, presenting a panoramic event for the swine industry. Since its inaugural edition in 2012 and through thirteen successful iterations, the conference has established itself as a crucial hub for global dialogue and knowledge sharing within the swine industry. This year's event attracted professional visitors from nearly 20 countries and regions including China's Hong Kong, Macao, and Taiwan, establishing itself as a communication and cooperation platform for the swine industry rooted in Asia with global reach. As a first-time exhibitor, VJTBio ignited significant on-site interest and delivered an impressive performance with its core products and professional presentation.
01. Successful Debut Generates Significant Buzz
At this exhibition, VJTBio presented a comprehensive showcase of its achievements in innovative drug efficacy, R&D capabilities, and technical services. The highlight was the blockbuster drug VJT101 (Recombinant Porcine Follitropin Fc Fusion Protein for Injection), which marks a key breakthrough as the first in the animal pharmaceutical field to utilize a CHO high-efficiency expression technology platform. Its research, development, and production strictly adhere to international biopharmaceutical development standards, ensuring safety, efficacy, and controllable quality. Concurrently, VJTBio's technical service team, centering on products, has established comprehensive solutions addressing core issues such as reproductive management, refined farm operations, and biosecurity. Through the synergy between products and technologies, the company effectively tackles a series of industry pain points, including resolving second-litter syndrome, improving the utilization rate of replacement gilts, enhancing batch farrowing efficiency, and addressing estrus issues in overdue sows.
Clinical trial data indicate that the use of this product leads to breakthrough improvements in both the number of litters per sow per year and the PSY (Pigs Weaned per Sow per Year). Furthermore, as a homologous recombinant protein drug, it possesses natural and safe characteristics, offering significant advantages in safety. The product can be used repeatedly, meeting the needs of modern large-scale farming and providing a more efficient and safer reproductive management solution for the industry. Proven by trial results, the product can greatly enhance reproductive efficiency, effectively reduce breeding costs, and significantly increase farm profitability.
02. A Fruitful First Exhibition
Leveraging its product value and robust technology, the booth attracted a continuous stream of visitors from the very start of the exhibition. Attendees showed strong interest and close attention not only towards the R&D background and mechanism of action of the new veterinary drug but also to the application scenarios and usage protocols for other key products. Swine industry professionals from China and abroad engaged in in-depth discussions covering technical details of products, industry development trends, and potential cooperation models. Domestic enterprises focused more on product compatibility with their own breeding systems and explored practical cooperation pathways, while international visitors concentrated on the product's prospects for global application and discussed opportunities for collaboration. The on-site outcomes were substantial and rewarding.
VJTBio's first participation in the World Pork Expo & Leman China Swine Conference proved highly rewarding. Through exchanges with domestic and international industry partners, the company not only enhanced the recognition of its brand and products within the industry but also gained insights into cutting-edge market demands. These insights have provided diverse directions for the company's future product development and technological optimization. Looking ahead, VJTBio anticipates meeting global partners on more industry platforms worldwide. Supported by high-quality products, the company is committed to deepening communication and cooperation, contributing Chinese solutions to the sustainable and high-quality development of the global animal husbandry industry.
